Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments

Drug repurposing has increased in recent years as an attractive option for treating a number of diseases. Compared to those brought forward via traditional chemical development, drugs intended for repurposing can enter the market faster and with lower investment from pharmaceutical companies. However, a common trend is to focus on diseases that yield higher returns to the industry, such as cancer and common metabolic and inflammatory conditions, resulting in orphan illnesses and neglected tropical diseases having fewer repurposing options for affected patients. In addition, certain legal concerns, including limited patent coverage for the repurposed drugs and pharmacological challenges in performing clinical trials, reduce the likelihood of success. In this review, we discuss the most important concerns that affect the pathway of drug repurposing, with special emphasis on the economic revenues, government-industry associations, and legal considerations that together impact the pharmaceutical industry?s decision-making on which compounds may be eligible for repurposing. ? 2020 IMSS. Published by

Automated summary

Drug repurposing is an attractive option for treating diseases, but there are challenges such as focusing on specific diseases, lack of options for orphan diseases, legal concerns, and challenges in clinical trials.